[Mastech Digital Q2 2025 Earnings Release](index=1&type=section&id=Mastech%20Digital%20Q2%202025%20Earnings%20Release) [Financial Highlights](index=1&type=section&id=Financial%20Highlights) The company reported a 2% sequential revenue growth to $49.1 million, though GAAP net income declined significantly due to one-time costs [Overall Performance](index=1&type=section&id=Overall%20Performance) Q2 2025 vs. Q2 2024 Performance | Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | Revenues | $49.1M | $49.5M | -0.8% | | Gross Profits | $13.8M | $14.0M | -1.4% | | Gross Margin | 28.1% | 28.2% | -10 bps | | GAAP Net Income | $0.1M | $1.4M | -92.8% | | GAAP Diluted EPS | $0.01 | $0.12 | -91.7% | | Non-GAAP Net Income | $1.8M | $2.2M | -18.2% | | Non-GAAP Diluted EPS | $0.15 | $0.19 | -21.1% | Q2 2025 vs. Q1 2025 Performance | Metric | Q2 2025 vs. Q1 2025 | Note | | :--- | :--- | :--- | | Consolidated Revenues | +2% | From $48.3M to $49.1M | | Consolidated Gross Margins | +147 bps | - | | GAAP Diluted EPS | $0.01 | vs. ($0.12) | | Non-GAAP Diluted EPS | $0.15 | vs. $0.06 | - Q2 2025 results included **$0.9 million** of combined severance and Finance & Accounting transition costs, while Q1 2025 included **$1.4 million** of severance expense[5](index=5&type=chunk) [Segment Performance](index=1&type=section&id=Segment%20Performance) - The **IT Staffing Services** segment achieved a 3% sequential revenue increase, driven by higher bill rates and disciplined pricing[4](index=4&type=chunk)[5](index=5&type=chunk) - The **Data and Analytics Services** segment experienced softer activity with order bookings of $5.8 million, reflecting cautious client spending[5](index=5&type=chunk)[6](index=6&type=chunk) [Management Commentary and Financial Position](index=2&type=section&id=Management%20Commentary%20and%20Financial%20Position) Management noted resilient performance and market stabilization while maintaining a strong financial position with no bank debt - CEO Nirav Patel highlighted early signs of market stabilization and the company's strategic focus on becoming a partner for AI-first transformations[7](index=7&type=chunk) - The company maintains a strong financial position with **$27.9 million in cash**, no bank debt, and **$22.2 million** in borrowing availability[7](index=7&type=chunk) - Days Sales Outstanding (DSO) was **53 days**, which is within the company's target range[7](index=7&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) This section provides the unaudited condensed consolidated financial statements for the second quarter ended June 30, 2025 [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Balance Sheet Summary (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $27,933 | $27,742 | | Total current assets | $65,659 | $66,205 | | Total assets | $110,392 | $111,484 | | Total current liabilities | $19,718 | $20,577 | | Total liabilities | $22,582 | $24,050 | | Total shareholders' equity | $87,810 | $87,434 | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Statement of Operations Summary (in thousands, except per share data) | Metric | Three Months ended June 30, 2025 | Three Months ended June 30, 2024 | | :--- | :--- | :--- | | Revenues | $49,097 | $49,534 | | Gross profit | $13,820 | $13,980 | | Income from operations | $27 | $1,693 | | Net income | $135 | $1,391 | | Diluted EPS | $0.01 | $0.12 | [Reconciliation of GAAP to Non-GAAP Measures](index=7&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Measures) Q2 2025 GAAP to Non-GAAP Reconciliation (in thousands) | Description | Amount | | :--- | :--- | | GAAP Net Income | $135 | | Amortization of acquired intangible assets | $649 | | Stock-based compensation | $714 | | Severance expense | $232 | | Finance and accounting transition expense | $688 | | Income tax adjustments | ($588) | | **Non-GAAP Net Income** | **$1,830** | - Non-GAAP measures exclude items like amortization, stock-based compensation, and one-time expenses to provide a more meaningful comparison of operational performance[11](index=11&type=chunk)[12](index=12&type=chunk)[13](index=13&type=chunk) [Supplemental Financial Information (by Segment)](index=8&type=section&id=Supplemental%20Financial%20Information%20(by%20Segment)) Q2 2025 Segment Revenues (in thousands) | Segment | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Data and analytics services | $8,589 | $8,876 | | IT staffing services | $40,508 | $40,658 | | **Total revenues** | **$49,097** | **$49,534** | Q2 2025 Segment Gross Margin % | Segment | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Data and analytics services | 45.2% | 49.2% | | IT staffing services | 24.5% | 23.6% | | **Total gross margin %** | **28.1%** | **28.2%** | [Disclosures](index=2&type=section&id=Disclosures) This section details the rationale for using non-GAAP measures and includes a standard forward-looking statements disclaimer - The company presents non-GAAP measures to supplement GAAP results, believing they offer investors useful information for period-to-period comparisons[9](index=9&type=chunk)[10](index=10&type=chunk) - A cost-cutting initiative to transition finance functions to India is expected to cost **$2.0 million** and yield annual savings of **$1.2 million** post-transition[14](index=14&type=chunk) - The release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially[15](index=15&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-36589 WILHELMINA INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) | ...

PART I — FINANCIAL INFORMATION [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) This section presents Adaptimmune Therapeutics plc's unaudited condensed consolidated financial statements for the three and six months ended June 30, 2025, detailing financial position, performance, cash flows, and significant subsequent events Condensed Consolidated Balance Sheet Highlights (in thousands) | Balance Sheet Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $26,061 | $91,139 | | Marketable securities | $0 | $60,466 | | Total current assets | $78,115 | $188,169 | | Total assets | $130,633 | $245,963 | | **Liabilities & Equity** | | | | Total current liabilities | $51,513 | $64,527 | | Total liabilities | $201,591 | $234,114 | | Total stockholders' equity | $(70,958) | $11,849 | Condensed Consolidated Statements of Operations Highlights (in thousands, except per share data) | Income Statement Item | Six months ended June 30, 2025 | Six months ended June 30, 2024 | | :--- | :--- | :--- | | Product revenue, net | $15,126 | $0 | | Development revenue | $5,836 | $133,909 | | **Total revenue** | **$20,962** | **$133,909** | | Research and development | $(51,836) | $(75,655) | | Selling, general and administrative | $(41,767) | $(38,815) | | **(Loss)/profit from operations** | **$(76,021)** | **$19,439** | | **Net (loss)/profit** | **$(77,924)** | **$21,018** | | Net (loss)/profit per share, basic | $(0.05) | $0.01 | Condensed Consolidated Statements of Cash Flows Highlights (in thousands) | Cash Flow Item | Six months ended June 30, 2025 | Six months ended June 30, 2024 | | :--- | :--- | :--- | | Net cash (used in)/provided by operating activities | $(101,372) | $15,449 | | Net cash provided by/(used in) investing activities | $59,644 | $(1,101) | | Net cash (used in)/provided by financing activities | $(23,666) | $53,747 | | **Net (decrease)/increase in cash** | **$(65,428)** | **$67,659** | - The company has incurred a net loss of **$77.9 million** and used **$101.4 million** in cash from operating activities for the six months ended June 30, 2025 However, management believes that cash and cash equivalents will be sufficient for at least the next 12 months following the filing, primarily due to a significant asset sale and restructuring that occurred in July 2025[28](index=28&type=chunk)[31](index=31&type=chunk) - A significant subsequent event occurred on July 27, 2025, when the company entered into an Asset Purchase Agreement to sell its key cell therapy assets (TECELRA, letecel, afami-cel, uza-cel) to USWM CT, LLC for **$55.0 million** in cash upfront, plus potential future milestones up to **$30.0 million** The transaction closed on July 31, 2025[103](index=103&type=chunk)[104](index=104&type=chunk)[105](index=105&type=chunk) - In connection with the asset sale, the company announced a further restructuring on July 28, 2025, planning to reduce its remaining workforce by approximately **62%** This is expected to incur pre-tax costs of approximately **$7.0 million to $8.0 million**, primarily in the third quarter of 2025[109](index=109&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's strategic shift, including the sale of key assets and restructuring, analyzing financial results impacted by decreased collaboration revenue and initial product sales, while affirming sufficient liquidity post-asset sale - On July 27, 2025, the company agreed to sell its key assets, including TECELRA, letecel, afami-cel, and uza-cel, to US WorldMeds This transaction marks a significant strategic shift, with the company now planning to explore options for its remaining preclinical assets like PRAME and ADP-520[115](index=115&type=chunk)[120](index=120&type=chunk)[121](index=121&type=chunk) Comparison of Operations for the Three Months Ended June 30 (in thousands) | Metric | Q2 2025 | Q2 2024 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | **Revenue** | **$13,677** | **$128,231** | **$(114,554)** | **(89)%** | | Product revenue, net | $11,078 | $0 | $11,078 | N/A | | Development revenue | $2,599 | $128,231 | $(125,632) | (98)% | | R&D Expenses | $(22,979) | $(40,448) | $17,469 | (43)% | | SG&A Expenses | $(18,485) | $(19,083) | $598 | (3)% | | **Net (Loss)/Profit** | **$(30,340)** | **$69,521** | **$(99,861)** | **(144)%** | Comparison of Operations for the Six Months Ended June 30 (in thousands) | Metric | H1 2025 | H1 2024 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | **Revenue** | **$20,962** | **$133,909** | **$(112,947)** | **(84)%** | | Product revenue, net | $15,126 | $0 | $15,126 | N/A | | Development revenue | $5,836 | $133,909 | $(128,073) | (96)% | | R&D Expenses | $(51,836) | $(75,655) | $23,819 | (31)% | | SG&A Expenses | $(41,767) | $(38,815) | $(2,952) | 8% | | **Net (Loss)/Profit** | **$(77,924)** | **$21,018** | **$(98,942)** | **(471)%** | - The significant decrease in development revenue in 2025 is primarily due to the termination of the Genentech collaboration in April 2024, which resulted in a one-time cumulative catch-up revenue recognition of **$101.3 million** in Q2 2024[163](index=163&type=chunk)[178](index=178&type=chunk) - Total Liquidity, a non-GAAP measure combining cash, cash equivalents, and marketable securities, was **$26.1 million** as of June 30, 2025, a sharp decline from **$151.6 million** at December 31, 2024 However, the company received a **$55.0 million** cash payment from the asset sale in July 2025[190](index=190&type=chunk)[199](index=199&type=chunk) - Net cash used in operating activities was **$101.4 million** for the first six months of 2025, a stark contrast to the **$15.4 million** provided by operating activities in the same period of 2024 The change was driven by the absence of large upfront collaboration payments received in 2024 and cash outflows for redundancy payments in 2025[192](index=192&type=chunk)[193](index=193&type=chunk)[195](index=195&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=40&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company reports no material changes to its market risk exposure during the three months ended June 30, 2025, referring to the 2024 Annual Report for detailed discussion - There were no material changes to the Company's market risk during the second quarter of 2025[202](index=202&type=chunk) [Controls and Procedures](index=40&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2025, with no material changes to internal control over financial reporting during the quarter - Based on an evaluation as of June 30, 2025, the Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were effective[203](index=203&type=chunk)[204](index=204&type=chunk) - No material changes to the company's internal control over financial reporting were identified during the quarter ended June 30, 2025[205](index=205&type=chunk) PART II — OTHER INFORMATION [Legal Proceedings](index=40&type=section&id=Item%201.%20Legal%20Proceedings) The company settled litigation with The University of Texas M.D. Anderson Cancer Center on July 16, 2025, with the financial impact deemed immaterial to its operations - On July 16, 2025, the company settled litigation with The University of Texas M.D Anderson Cancer Center concerning a 2016 strategic alliance agreement[95](index=95&type=chunk)[206](index=206&type=chunk) - The company asserts that the financial obligations of the settlement are not material and are not expected to have a material adverse effect on its financial position[96](index=96&type=chunk)[207](index=207&type=chunk) [Risk Factors](index=41&type=section&id=Item%201A.%20Risk%20Factors) This section highlights the risk of non-compliance with Nasdaq's minimum bid price requirement, detailing the company's transfer to the Nasdaq Capital Market and the extended period to regain compliance - The company is not in compliance with Nasdaq's minimum bid price requirement, as its American Depositary Shares (ADSs) traded below **$1.00** for over 30 consecutive business days, receiving a notice on November 1, 2024[211](index=211&type=chunk) - On May 1, 2025, Nasdaq approved the company's application to transfer its listing to the Nasdaq Capital Market, granting an additional 180-day compliance period to regain the minimum **$1.00** bid price[212](index=212&type=chunk) - Failure to regain compliance with Nasdaq's listing rules could result in the delisting of the company's ADSs, which would adversely affect market price, liquidity, and the ability to raise capital[213](index=213&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=41&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities or use of proceeds from such sales during the period - None reported for the period[214](index=214&type=chunk) [Defaults Upon Senior Securities](index=41&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon its senior securities during the period - None reported for the period[215](index=215&type=chunk) [Mine Safety Disclosures](index=42&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's business operations - Not applicable[216](index=216&type=chunk) [Other Information](index=42&type=section&id=Item%205.%20Other%20Information) The company states that during the three-month period ended June 30, 2025, none of its directors or officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement - No directors or officers adopted, modified, or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the second quarter of 2025[217](index=217&type=chunk) [Exhibits](index=42&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Quarterly Report on Form 10-Q, including the Asset Purchase Agreement and required officer certifications - The exhibits filed with this report include the Asset Purchase Agreement dated July 27, 2025, and required officer certifications under Sections 302 and 906 of the Sarbanes-Oxley Act[218](index=218&type=chunk)

Exhibit 99.1 Solaris Resources Inc. Condensed Consolidated Interim Financial Statements For the three and six months ended June 30, 2025 and 2024 (Unaudited) Solaris Resources Inc. Condensed Consolidated Interim Statements of Financial Position (Unaudited – In thousands of United States dollars) | | | | June 30, | | December 31, | | --- | --- | --- | --- | --- | --- | | | Note | | 2025 | | 2024 | | Assets | | | | | | | Current assets | | | | | | | Cash and cash equivalents | | $ | 47,047 | $ | 31,738 | | Pr ...

Exhibit 99.1 | Partner | Event | | --- | --- | | Rezolute | In May, the company announced the U.S. Food and Drug Administration (FDA) granted Breakthrough | | | Therapy Designation (BTD) to its investigational therapy, ersodetug, for the treatment of hypoglycemia | | | caused by tumor HI.1 | | | In May, Rezolute announced the completion of enrollment in the Phase 3 sunRIZE study. Topline data are | | | anticipated in December of 2025.2 As a result of Rezolute completing enrollment in the study, XOMA | | | R ...

Exhibit 99.1 XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty's recently announced acquisition of LAVA Therapeutics. Company acquisitions: Announced XOMA Royalty's acquisitions of Turnstone Biologics, LAVA Therapeutics, and HilleVax; ac ...

[Fiscal 2025 Fourth Quarter and Full Year Results](index=1&type=section&id=Fiscal%202025%20Fourth%20Quarter%20and%20Full%20Year%20Results) [Overall Performance Summary](index=1&type=section&id=Overall%20Performance%20Summary) Fiscal 2025 revenue decreased 2% to **$942.7 million**, while operating income rose 9% to **$122.1 million**, despite a Q4 revenue decline and operating loss Overall Financial Performance | Metric | Q4 FY2025 | Q4 FY2024 | Change | FY 2025 | FY 2024 | Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | **Revenues** | $154.1M | $186.1M | -17% | $942.7M | $959.3M | -2% | | **Operating (Loss) Income** | $(25.8)M | $(8.9)M | -191% | $122.1M | $111.9M | +9% | | **Adjusted Operating (Loss) Income** | $(1.3)M | $13.1M | NM | $222.5M | $211.5M | +5% | - Hosted nearly **6 million guests** at more than **975 events** during fiscal 2025, including concerts, special events, and sports[2](index=2&type=chunk) - The *Christmas Spectacular* production sold approximately **1.1 million tickets** across **200 shows**, achieving another year of record-setting revenues[2](index=2&type=chunk) - The company repurchased approximately **$40 million** of its Class A common stock during fiscal 2025[2](index=2&type=chunk) - Executive Chairman and CEO James L. Dolan stated, "We see this momentum continuing in fiscal 2026, and believe we are well positioned to drive solid revenue and adjusted operating income growth in the year ahead"[3](index=3&type=chunk) [Segment Performance Analysis (Q4 FY2025)](index=2&type=section&id=Segment%20Performance%20Analysis%20(Q4%20FY2025)) [Entertainment Offerings, Arena License Fees and Other Leasing](index=2&type=section&id=Entertainment%20Offerings%2C%20Arena%20License%20Fees%20and%20Other%20Leasing) Q4 FY2025 entertainment offerings revenue decreased 17% to **$118.7 million** due to lower event-related revenues, partially offset by a 6% increase in arena license fees, with direct operating expenses falling 14% - Entertainment offerings revenues decreased by **$24.1 million** (17%) compared to the prior year quarter, driven by lower event-related revenues and decreased revenue sharing with MSG Sports[6](index=6&type=chunk) - Event-related revenues fell by **$21.6 million**, mainly from a decrease in the number of concerts at Madison Square Garden Arena and a shift in event mix from promoted events to rentals[13](index=13&type=chunk) - Arena license fees and other leasing revenues increased by **$0.5 million** (6%), primarily due to higher other leasing revenues[7](index=7&type=chunk) - Direct operating expenses for this segment decreased by **$14.2 million** (14%), mainly due to lower event-related expenses[8](index=8&type=chunk) [Food, Beverage and Merchandise](index=2&type=section&id=Food%2C%20Beverage%20and%20Merchandise) Q4 FY2025 food, beverage, and merchandise revenues declined 24% to **$26.4 million** due to fewer events, with direct operating expenses decreasing 27% to **$16.5 million** Food, Beverage and Merchandise Performance | Metric | Q4 FY2025 | Change vs Q4 FY2024 | Reason | | :--- | :--- | :--- | :--- | | **Revenues** | $26.4M | -$8.3M (-24%) | Fewer games and concerts at The Garden | | **Direct Operating Expenses** | $16.5M | -$6.2M (-27%) | Lower costs in line with reduced sales volume | [Selling, General and Administrative Expenses](index=2&type=section&id=Selling%2C%20General%20and%20Administrative%20Expenses) Q4 FY2025 selling, general and administrative expenses increased 7% to **$59.9 million**, primarily driven by higher employee compensation and benefits - Q4 SG&A expenses increased by **$4.1 million**, or 7%, to **$59.9 million**[11](index=11&type=chunk) - The primary driver for the increase was higher employee compensation and related benefits, which was partially offset by lower rent expense[11](index=11&type=chunk) [Operating Loss and Adjusted Operating (Loss) Income](index=2&type=section&id=Operating%20Loss%20and%20Adjusted%20Operating%20(Loss)%20Income) Q4 FY2025 operating loss widened by **$16.9 million** to **$25.8 million**, and adjusted operating income swung to a **$1.3 million** loss, driven by lower revenues and higher SG&A expenses Operating and Adjusted Operating Income | Metric | Q4 FY2025 | Q4 FY2024 | Change | | :--- | :--- | :--- | :--- | | **Operating Loss** | $(25.8)M | $(8.9)M | +$16.9M | | **Adjusted Operating (Loss)/Income** | $(1.3)M | $13.1M | -$14.4M | - The decline in operating results was primarily due to lower revenues and, to a lesser extent, higher selling, general and administrative expenses, partially offset by lower direct operating expenses[12](index=12&type=chunk) [Financial Statements](index=4&type=section&id=Financial%20Statements) [Consolidated Statements of Operations](index=4&type=section&id=Consolidated%20Statements%20of%20Operations) Fiscal year 2025 consolidated operations show total revenues of **$942.7 million** and operating income of **$122.1 million**, but net income significantly dropped to **$37.4 million** due to tax changes Fiscal Year Ended June 30 | Metric (in thousands) | 2025 | 2024 | | :--- | :--- | :--- | | **Total revenues** | $942,734 | $959,265 | | **Operating income** | $122,092 | $111,941 | | **Net income** | $37,431 | $144,300 | | **Diluted EPS** | $0.77 | $2.97 | Three Months Ended June 30 | Metric (in thousands) | 2025 | 2024 | | :--- | :--- | :--- | | **Total revenues** | $154,138 | $186,074 | | **Operating loss** | $(25,754) | $(8,860) | | **Net (loss) income** | $(27,177) | $66,927 | | **Diluted (Loss) EPS** | $(0.57) | $1.41 | [Consolidated Balance Sheets](index=6&type=section&id=Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets increased to **$1.67 billion** and total liabilities to **$1.68 billion**, with cash rising to **$43.5 million** and the total deficit narrowing Consolidated Balance Sheets Summary | Metric (in thousands) | June 30, 2025 | June 30, 2024 | | :--- | :--- | :--- | | **Total current assets** | $237,132 | $219,084 | | **Total assets** | $1,669,842 | $1,552,707 | | **Total current liabilities** | $502,401 | $505,823 | | **Total liabilities** | $1,683,142 | $1,575,872 | | **Total deficit** | $(13,300) | $(23,165) | - Cash, cash equivalents and restricted cash increased to **$43.5 million** from **$33.6 million** in the prior year[28](index=28&type=chunk) - Long-term debt, net of deferred financing costs, decreased to **$568.8 million** from **$599.2 million**[28](index=28&type=chunk) [Selected Cash Flow Information](index=7&type=section&id=Selected%20Cash%20Flow%20Information) For FY2025, net cash from operating activities increased to **$115.3 million**, while investing activities used **$23.7 million** and financing activities used **$81.6 million**, resulting in a **$10.0 million** net cash increase Selected Cash Flow Summary | Metric (in thousands) | FY 2025 | FY 2024 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $115,297 | $111,266 | | **Net cash used in investing activities** | $(23,693) | $(62,371) | | **Net cash used in financing activities** | $(81,621) | $(99,695) | | **Net increase (decrease) in cash** | $9,983 | $(50,800) | [Appendix](index=3&type=section&id=Appendix) [Non-GAAP Financial Measures Reconciliation](index=3&type=section&id=Non-GAAP%20Financial%20Measures%20Reconciliation) This section reconciles GAAP operating income to adjusted operating income, showing how **$122.1 million** operating income was adjusted to **$222.5 million** for FY2025, a key internal performance indicator - Adjusted operating income is defined as operating income excluding items such as depreciation, amortization, share-based compensation, restructuring charges, and merger/spin-off costs[16](index=16&type=chunk) Reconciliation to Adjusted Operating Income (FY 2025) | Description | Amount (in thousands) | | :--- | :--- | | **Operating income** | **$122,092** | | Depreciation and amortization | $57,768 | | Impairment of long-lived assets | $11,202 | | Share-based compensation | $27,694 | | Restructuring charges | $1,055 | | Other adjustments | $2,695 | | **Adjusted operating income** | **$222,506** | - The company uses revenues and adjusted operating income as its most important internal indicators of business performance and management effectiveness[17](index=17&type=chunk) [Company Overview and Other Information](index=3&type=section&id=Company%20Overview%20and%20Other%20Information) Madison Square Garden Entertainment Corp. is a prominent live entertainment company operating renowned venues and producing the *Christmas Spectacular*, with the report including standard forward-looking statement disclaimers - The company's portfolio includes world-renowned venues in New York and Chicago, such as Madison Square Garden and The Chicago Theatre[15](index=15&type=chunk) - Features the original production, the *Christmas Spectacular Starring the Radio City Rockettes*, a holiday tradition for over 90 years[15](index=15&type=chunk) - The press release includes a forward-looking statements disclaimer, cautioning investors about risks and uncertainties that could affect future performance[18](index=18&type=chunk)

Table of Contents ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from __________to__________ Commission File Number: 001-39801 XOMA Royalty Corporation UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the quarterly period ended June 30, 2025 OR Securities registered pursuant to Section 12(b) of the Act: | Title of each class: | T ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from __________to__________ Commission File Number: 001-39801 XOMA Royalty Corporation (Exact name of Registrant as specified in its charter) (State or other jurisdiction of ...

[Business and Financial Highlights](index=1&type=section&id=Business%20and%20Financial%20Highlights) [Q2 2025 Business Update](index=1&type=section&id=Q2%202025%20Business%20Update) Adaptimmune reported strong commercial growth for TECELRA in Q2 2025, with sales increasing over 150% compared to Q1, and strategically agreed to sell its main cell therapy assets to US WorldMeds for $55 million upfront plus potential milestones, leading to debt repayment and restructuring to focus on remaining PRAME and CD70 programs - Entered into a definitive agreement to sell TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds[1](index=1&type=chunk) US WorldMeds Transaction Details | Term | Value | | :--- | :--- | | Upfront Payment | $55 million | | Future Milestone Payments | Up to $30 million | - Q2 TECELRA sales reached **$11.1 million** from 16 patients invoiced, representing over **150% growth** compared to Q1 2025[1](index=1&type=chunk)[2](index=2&type=chunk) - Following the asset sale, Adaptimmune repaid its debt facility with Hercules Capital and is restructuring to maximize value from remaining assets, including programs targeting PRAME and CD70[1](index=1&type=chunk)[2](index=2&type=chunk) - The company has maintained a **100% commercial manufacturing success rate** through the end of Q2, and the network of Authorized Treatment Centers (ATCs) is nearing completion with 30 centers accepting referrals[2](index=2&type=chunk) [Q2 2025 Financial Highlights](index=1&type=section&id=Q2%202025%20Financial%20Highlights) For the second quarter of 2025, Adaptimmune's revenue was $13.7 million, a significant decrease from $128.2 million in Q2 2024, primarily due to the termination of the Genentech collaboration, resulting in a net loss of $30.3 million compared to a prior-year profit, with operating expenses decreasing due to lower R&D costs, and cash and cash equivalents at $26.1 million as of June 30, 2025 Key Financial Metrics (Three Months Ended June 30) | Metric | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Revenue | $13.7M | $128.2M | -89.3% | | R&D Expenses | $23.0M | $40.4M | -43.1% | | SG&A Expenses | $18.5M | $19.1M | -3.1% | | Net (Loss)/Profit | $(30.3)M | $69.5M | N/A | | EPS (Diluted) | $(0.02) | $0.04 | N/A | Key Financial Metrics (Six Months Ended June 30) | Metric | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Revenue | $21.0M | $133.9M | -84.3% | | R&D Expenses | $51.8M | $75.7M | -31.6% | | SG&A Expenses | $41.8M | $38.8M | +7.7% | | Net (Loss)/Profit | $(77.9)M | $21.0M | N/A | | EPS (Diluted) | $(0.05) | $0.01 | N/A | - The significant decrease in revenue for the six months ended June 30, 2025, was primarily due to the termination of the Genentech collaboration in April 2024, which had resulted in a **$101.3 million cumulative catch-up adjustment** in the prior year period[3](index=3&type=chunk) - Cash and cash equivalents were **$26.1 million** as of June 30, 2025, down from **$91.1 million** at December 31, 2024[3](index=3&type=chunk) - The company believes its cash and cash equivalents are sufficient to fund planned operations for at least 12 months following the Q2 2025 filing, as a result of the US WorldMeds transaction and debt repayment[5](index=5&type=chunk) [Financial Statements](index=6&type=section&id=Financial%20Statements) [Condensed Consolidated Statement of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statement%20of%20Operations) For the six months ended June 30, 2025, total revenue was $21.0 million, a sharp decline from $133.9 million in the same period of 2024, driven by a near-total drop in development revenue partially offset by new product revenue of $15.1 million, with total operating expenses decreasing to $97.0 million from $114.5 million, resulting in an operating loss of $76.0 million and a net loss of $77.9 million for the first half of 2025 Statement of Operations Summary (in thousands) | Line Item | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Total Revenue | $20,962 | $133,909 | | Total Operating Expenses | $(96,983) | $(114,470) | | (Loss)/Profit from Operations | $(76,021) | $19,439 | | Net (Loss)/Profit | $(77,924) | $21,018 | | Net (Loss)/Profit per Share (Diluted) | $(0.05) | $0.01 | [Condensed Consolidated Balance Sheets](index=7&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, Adaptimmune's total assets were $130.6 million, a significant decrease from $246.0 million at the end of 2024, primarily due to a reduction in cash and marketable securities, while total liabilities also decreased to $201.6 million from $234.1 million mainly from a reduction in borrowings, resulting in total stockholders' equity turning to a deficit of $71.0 million from a positive $11.8 million at year-end 2024 Balance Sheet Summary (in thousands) | Line Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $26,061 | $91,139 | | Total Current Assets | $78,115 | $188,169 | | **Total Assets** | **$130,633** | **$245,963** | | Total Current Liabilities | $51,513 | $64,527 | | **Total Liabilities** | **$201,591** | **$234,114** | | **Total Stockholders' Equity** | **$(70,958)** | **$11,849** | [Condensed Consolidated Cash Flow Statement](index=8&type=section&id=Condensed%20Consolidated%20Cash%20Flow%20Statement) For the first six months of 2025, net cash used in operating activities was $101.4 million, a significant outflow compared to a $15.4 million inflow in the prior year period, driven by the net loss and changes in working capital, with net cash provided by investing activities at $59.6 million primarily from marketable securities maturity, and net cash used in financing activities at $23.7 million mainly due to borrowings repayment, resulting in a net decrease in cash of $65.4 million for the period Cash Flow Summary (Six Months Ended June 30, in thousands) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash (used in)/provided by operating activities | $(101,372) | $15,449 | | Net cash provided by/(used in) investing activities | $59,644 | $(1,101) | | Net cash (used in)/provided by financing activities | $(23,666) | $53,747 | | **Net (decrease)/increase in cash** | **$(65,428)** | **$67,659** | [Non-GAAP Financial Measures](index=5&type=section&id=Non-GAAP%20Financial%20Measures) [Reconciliation of Total Liquidity](index=5&type=section&id=Reconciliation%20of%20Total%20Liquidity) The company uses the non-GAAP measure 'Total Liquidity,' defined as the sum of cash, cash equivalents, and marketable securities, which as of June 30, 2025, was $26.1 million, a significant decrease from $151.6 million at the end of 2024, primarily due to the sale or maturity of all marketable securities - Total Liquidity is a non-GAAP financial measure defined as the total of cash and cash equivalents and marketable securities (available-for-sale debt securities)[8](index=8&type=chunk) Reconciliation of Total Liquidity (in thousands) | | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $26,061 | $91,139 | | Marketable securities | — | $60,466 | | **Total Liquidity** | **$26,061** | **$151,605** |